Investment

Incubation by Factor Biosciences provides Day 1 access to cell lines, scientific expertise, lab space and resources

Seed funding will be utilized to achieve significant de-risking to in vivo proof of concept for Exacis’ first product by validating the following:

• • Applicability of mRNA-based iPSC generation technology and approach to cancer therapeutics development
  • mRNA based combinatorial editing approach, including structure and function of edits
  • Clonal aspect of iPSC expansion
  • iPSC to ExaCAR-T cell differentiation approach
  • Relevance of edit selection toward achievement of immune related goals
  • Overall function of cell therapy in an in vivo tumor model

Highly scalable and efficient, GMP ready manufacturing process, leveraging perpetual cell banking and unlimited cell supply, for immediate transfer to contract manufacturer for cell development once validated

Efficient regulatory pathway leveraging multiple accelerated programs in the US and European Union

Capital efficiency achieved through reproducible approach for application of technologies to develop subsequent products (including NK)

Exacis has exclusive rights to a robust patent estate for use in oncology

Multibillion-dollar market potential in the US and EU

Very active investment and acquisition space with more than 5 IPOs in past 24 months